Alison is a recognized global expert in all aspects of market access and reimbursement strategies built over 35 years’ experience in the pharmaceutical industry with 28 years’ specific to market access. Upon joining DRG Abacus in 2018, Alison established the Global Access Advisory to provide strategic end-to-end guidance for clients navigating the roadmap to market access. An inaugural member of the first market access team in the pharmaceutical industry, Alison further developed her career at GSK, Novartis, AstraZeneca, and Baxalta, holding senior leadership positions at Local, European, and Global levels.
Siva's work centers around being a catalyst to globally enable healthcare industry players and payers to arrive at an optimal solution for patient access. Siva pulls on his experience of launching assets in more than 2 dozen countries, as well as his years of creating and driving strategy across the product lifecycle to meet regulatory and payer needs. Siva has an established network of relationships with payers (U.S and Ex-U.S), HTA stakeholders, international/national societies, KOLs and Patient Advocacy Groups and is widely published.
Helen leads the Clinical Outcomes Assessment practice, providing strategic input on measurement strategy and patient outcomes research. An advocate for innovative and creative research methods, Helen has 10 years’ experience of developing and validating clinical outcome assessment (COA) measures including patient-reported outcomes (PROs) and clinician-reported outcomes (ClinROs) for clinical trials and practice in line with regulatory (FDA, EMA) requirements. Helen holds an MSc (Merit) in Health Psychology from Sheffield Hallam University and a BA(Hons) in Psychology from the University of Manchester.
Mary leads the Value Communications practice, partnering with clients to facilitate communication of evidence-based value both internally and externally. Mary has been part of Decision Resources Group, serving the pharmaceutical industry, for the last 18 years, with her earliest work focused on analysing European healthcare systems before the term ‘market access’ was coined. After achieving a distinction in her MPH (advanced statistics, epidemiology), Mary went on to run DRG's first payer research product focusing on success factors for favourable reimbursement of pharmaceuticals, leading the portfolio expansion to cover Europe and key emerging markets. Prior to joining DRG Mary worked for Oxfam and for Amnesty International.
Sunita leads the Systematic Review and Network Meta-Analysis teams. Sunita is a business leader with 20 years’ experience, having spent the last 13 years in the pharmaceutical service industry with experience spanning cardiovascular research, health economics & outcomes research, knowledge management, market access, market research, medical communications, molecular diagnostics, and scientific writing. Sunita formerly worked in tertiary hospitals and multinational pharmaceutical companies in India and established and managed businesses for national and international clients. Sunita has a PhD in Applied Biology (Molecular Biology) and a Master's degree in Microbiology from the University of Mumbai, and a Post-Graduate Diploma in Global Health Policy from the London School of Hygiene and Tropical Medicine. She is also trained in Knowledge Management, carried out at the Indian Institute of Management.
Kim is an experienced health professional with a successful track record in global pharmaceutical development and market access consultancy. Kim works with multi-disciplinary teams to deliver bespoke, high quality, commercially relevant projects to clients. Kim has been involved in health economics and outcomes research (HEOR) and market access for over 20 years, being part of the first pharmacoeconomics team in the industry (Glaxo) to address the needs of research and development (R&D), pricing and reimbursement (P&R), and affiliates with regards to market access. Kim has been a Senior Executive within established health outcomes consultancies for over 15 years, working across an extensive range of technical and strategic market access and HEOR projects for both global and local clients. Kim has a passion for enhancing the patient perspective in healthcare decision making, both in her work in global access consultancy and by shaping UK health policy through her ongoing work with Asthma UK.
Ruth leads the Health Technology Assessment practice at DRG Abacus. Ruth has overall responsibility for our health technology assessment (HTA) services and has been extensively involved in the development and strategic direction of HTAs, contributing in-depth knowledge of procedural processes and excellent relationships with the main HTA bodies in the United Kingdom. With extensive experience of managing HTA submissions, Ruth works closely with our clients and in-house team, advising manufacturers on their role and requirements, and significantly contributes in the development and communication of the HTA strategy and evidence generation planning from an early stage. Prior to joining DRG Abacus, Ruth worked for the National Institute for Health and Care Excellence (NICE) and has over 14 years’ experience in health outcomes research. Ruth has an MSc in Health Economics from the University of York.
Joan’s focus is to champion a profound understanding of our clients’ needs and create communications programs that demonstrate how our unique capabilities have the versatility to deliver effective solutions to the industry. An expert in strategtic positioning and communications, Joan's prior experience includes leading the go-to-market strategies for the clinical programs delivered by PMSI (now part of OPTUM), a leading US-based workers’ compensation pharmacy benefit manager. Joan developed the positioning and market launch for PMSI’s Population Risk Scorecard, winner of the Industry Innovator Award from The Institute for HealthCare Consumerism in 2013. Joan received a Bachelor of Science, Marketing, and a Master of Business Administration from the University of Scranton. She is a member of Beta Gamma Sigma International Honor Society and the Business Marketing Association.
Pam is Head of Operations of the DRG Abacus Global Health Economic and Outcomes Research (HEOR) business. Pam has 15 years’ experience in the consulting sector from a finance and operational perspective. Prior to joining DRG Abacus, Pam trained as an accountant and was Finance Director for a UK division of Philips NV.
Rachel has managed and advised on a range of global market access, value communication, and evidence generation projects for DRG Abacus clients. Rachel has a combination of experience within HEOR consultancy and the health care provider (HCP) sector. Having begun her career as a hospital manager in mental health services, Rachel moved into consultancy. Prior to her current role in DRG Abacus, she worked for a small consultancy where she was responsible for developing outcomes frameworks and commercial incentives for contracting for capitated outcomes based contracts around integrated, person-centered care.Rachel has a Masters in Biochemistry from the University of Oxford, a Masters in Public Health from Columbia University, and a Diploma in Health Economics from the University of York.
We are part of Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd.
DRG offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1,000 employees across 17 offices in North America, Europe and Asia.Our Company